The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
6 Primary · 0 Secondary · Reporting Duration: 0 (predose) to 24 hours postdose on Day 1 to Day 62
Experimental Treatment
37 Total Participants · 1 Treatment Group
Primary Treatment: Lu AF28996 · No Placebo Group · Phase 1
Age 45 - 75 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: